ChondroFiller and Liquid Cartilage are not the same thing

It is easy to assume these two names describe the same treatment, but they do not, and the difference changes how you should read every claim about credentials, recovery and cost. ChondroFiller is a specific product: a CE-marked collagen scaffold manufactured in Germany. Liquid Cartilage is the name of a procedure developed at London Cartilage Clinic that uses that scaffold. One is the material; the other is a way of delivering it.

ChondroFiller is an acellular collagen scaffold made by Meidrix Biomedicals in Germany and used across parts of Europe for nearly 20 years. As a material it can be delivered in two quite different ways. The first is a ChondroFiller injection: a non-surgical, ultrasound-guided outpatient treatment with no incision, no theatre admission and no general anaesthetic, suited to accessible lesions and smaller joints. The second is Liquid Cartilage, the Lee Liquid Cartilage Protocol, which is a keyhole (arthroscopic) surgical procedure. During minimally invasive surgery the surgeon prepares the cartilage defect and places the same ChondroFiller scaffold, then combines it with biological adjuncts such as platelet-rich fibrin and platelet-rich plasma and, where indicated, the patient's own mesenchymal stem cells harvested from bone marrow or fat. It is supported by peri-operative optimisation and a structured rehabilitation programme, and it is used for larger or load-bearing defects in joints such as the knee, hip, shoulder and ankle.

So when the sections below describe CE credentials and clinical evidence, they describe ChondroFiller, the device. Liquid Cartilage describes how that device is delivered surgically at London Cartilage Clinic. Keeping the two separate is the only way to compare the injection pathway and the surgical pathway fairly.

ChondroFiller's CE Class III credentials and what they mean

Trust is a reasonable first question when any treatment is described as regenerative. ChondroFiller is not a recent entrant into cartilage medicine: it was developed by Meidrix Biomedicals GmbH, a German biomedical company, and every unit is manufactured in Germany under strict quality standards. Over nearly two decades of clinical use it has accumulated a substantive body of data, making it a well-characterised device with an established European track record rather than an experimental option. In the UK it is imported under prescription, so patients receive the same German-manufactured product used in European clinical practice; nothing is reformulated or produced locally.

The device holds CE marking as a Class III medical device, the highest implant risk classification under European MDR. Class III sits at the top of the implant risk hierarchy, the same category as hip and knee replacements or cardiac stents. Reaching that classification is not a matter of self-certification: a manufacturer must submit its full clinical, technical and biological safety evidence to an independent notified body, which carries out a structured review and must grant approval before the device can be placed on the market. There is no shortcut.

What comes under that scrutiny for ChondroFiller is an acellular scaffold composed of purified murine-derived (rat) Type I collagen. The collagen contains no living cells, so there is no donor tissue and no requirement for a prior biopsy from the patient. The scaffold's role is to provide a structural matrix within the defect; the patient's own progenitor cells, recruited from the surrounding tissue, then populate and progressively replace it over time. The Class III assessment covers the biological tolerability of this source material alongside manufacturing controls and clinical evidence.

One boundary is worth stating plainly: CE marking is European regulatory approval and does not extend to the United States. ChondroFiller holds no FDA authorisation and has no active US trial, which limits the breadth of independent international regulatory validation. The European review under MDR is, however, substantive, and for UK patients CE Class III provides a clear and recognised regulatory basis for private clinical use following Brexit.

How ChondroFiller is delivered: injection versus Liquid Cartilage surgery

The same scaffold reaches the joint by two distinct routes, and which one suits you depends on the size and location of the defect, the joint involved and whether the surface can be reached without surgery. This decision is made at assessment, not assumed in advance.

In the ChondroFiller injection pathway, a clinician places the scaffold under ultrasound guidance during an outpatient appointment, with no general anaesthetic, no incisions and no theatre admission. The product arrives in a ready-to-use dual-chamber syringe holding a purified Type I collagen solution and a neutralising agent in separate compartments. As the syringe is activated the two components mix automatically at delivery, and the collagen gels within approximately three to five minutes of being placed, forming a stable hydrogel that sits precisely within the damaged area. The science behind what follows is acellular matrix-induced chondrogenesis: rather than delivering cells, the scaffold creates the structural environment for the patient's own progenitor cells, recruited from the surrounding synovium and subchondral bone, to migrate in, differentiate and gradually replace the scaffold with mature cartilage. Because there are no living donor cells, no biopsy is required and no bone drilling is needed. This route is typically used for suitable smaller joints and accessible lesions, where the scaffold acts as a regenerative layer.

Liquid Cartilage is the surgical pathway and is genuine keyhole surgery rather than a clinic injection. Under arthroscopy the surgeon debrides unstable cartilage and creates a stable defect rim without breaking the underlying bone plate, establishes a dry working chamber, and applies the ChondroFiller scaffold so it gels in place. The protocol then layers in biology: a platelet-rich fibrin primer, a platelet-rich plasma and tranexamic acid flood once the scaffold is secure, and, where indicated, the patient's own mesenchymal stem cells from bone marrow concentrate or micro-fragmented fat. Peri-operative optimisation and a phased rehabilitation programme, often with protected weight-bearing in the early weeks, support the repair. Because it is surgery, it involves theatre, anaesthetic and a structured recovery, and it is the preferred route for larger defects in the knee, hip, shoulder and ankle.

ChondroFiller's clinical evidence at one and three years

Published prospective data put the knee-specific IKDC score improvement at approximately 30 points, a figure that carries clinical weight because it exceeds the established minimum clinically important difference of 16.7 points, the threshold at which patients themselves report a meaningful change in daily function. Gains at this level represent a measurable shift in what patients can do rather than a marginal adjustment.

On MRI, MOCART scores of 81.6 to 84.3 at one year indicate that more than 80% of the structural defect has been filled and that the repair tissue integrates with the surrounding native cartilage. The functional gains are sustained at three-year follow-up in prospective studies, so the improvement is not an early post-procedure effect that fades over time.

Safety data sit alongside the structural outcomes. The complication rate across published series is approximately 0% and the reoperation rate approximately 3 to 8%. For context, autologous chondrocyte implantation and its matrix-assisted variant carry reported complication rates of up to 17% and reoperation rates of up to 37%, and microfracture has reoperation rates reported as high as 41%. These figures are reference points that allow the ChondroFiller safety profile to be read in proportion rather than an argument against surgery when surgery is genuinely indicated. One caveat deserves plain statement: most of the evidence summarised here is drawn from manufacturer-sponsored work, including version 09 of Meidrix Biomedicals' Clinical Evaluation Report dated April 2025, and independent randomised controlled trial data remain limited.

UK self-pay pricing for the injection and the surgical pathway

Because the two pathways involve very different resources, they are priced differently. The ChondroFiller injection is an outpatient procedure with no theatre, and London Cartilage Clinic's guide costs for it follow a straightforward volume-based structure, confirmed directly by the clinic:

• One box (1.0 ml) — £3,000
• Two boxes (up to 1.5 ml) — £5,500
• Three boxes (up to 2.3 ml) — £8,000

Each injection price is all-inclusive: consultation, ultrasound guidance, the implant itself and a six-week follow-up appointment. There is no separate itemisation of components and no variation by joint, so the same guide costs apply whether the injection is delivered to the knee, hip, ankle, shoulder, elbow, wrist or a small hand joint. The volume selected depends on defect size and is determined at assessment, so patients know which tier applies before they commit.

Liquid Cartilage, the arthroscopic surgical pathway, costs more than the injection because it adds theatre, anaesthetic and facility costs and may add biological adjuncts and a stem-cell harvest. Broader UK figures for arthroscopic cartilage procedures run from approximately £3,800 to £9,500, reflecting those added surgical costs, and the exact figure for a Liquid Cartilage procedure depends on the joint, the defect and the adjuncts used. It is confirmed case by case at consultation rather than quoted as a single price. All fees should be confirmed directly with the clinic at the time of booking, as guide costs may be updated. If you are weighing up which pathway is appropriate for your joint, a consultation at London Cartilage Clinic is the right starting point.